In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance
1999
Efficacy of XR9051 in Treating Drug Resistance in Tumors
publication
Evidence: moderate
Author Information
Author(s): Mistry P, Plumb J, Eccles S, Watson S, Dale I, Ryder H, Box G, Charlton P, Templeton D, Bevan P B
Primary Institution: Xenova Ltd
Hypothesis
XR9051 can reverse multidrug resistance in tumors by modulating P-glycoprotein activity.
Conclusion
XR9051 significantly enhances the effectiveness of various cancer drugs in tumor models.
Supporting Evidence
- XR9051 is a potent and specific inhibitor of P-glycoprotein.
- The drug was tested in various murine and human tumor models.
- Co-administration of XR9051 enhanced the anti-tumor activity of cytotoxic drugs.
- XR9051 was well-tolerated in combination with other treatments.
Takeaway
XR9051 is a new drug that helps other cancer treatments work better by fighting against drug resistance in tumors.
Methodology
The study evaluated XR9051's efficacy in murine and human tumor models and examined its pharmacokinetic profile.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website